Assessment of Autogenous Dentin Graft in Treatment of Infra-bony Defect

NCT ID: NCT05258006

Last Updated: 2022-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2022-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the present study was to evaluate the effect of demineralized autogenous dentine on treatment of infrabony defects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, the investigators tested the effect of demineralized autogenous dentine as a bone graft in treatment of stage III periodontitis in term of probing pocket depth reduction, mean gain in clinical attachment level, and bone gain in defect sites.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontitis (Stage 3)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open flap debridement + allograft bone (Maxgraft)

Group Type PLACEBO_COMPARATOR

Autogenous demineralized dentin nanoparticles

Intervention Type PROCEDURE

Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect

Open flap debridement + Autogenous demineralized nanoparticles

Group Type ACTIVE_COMPARATOR

Autogenous demineralized dentin nanoparticles

Intervention Type PROCEDURE

Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autogenous demineralized dentin nanoparticles

Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with good systemic health and no contraindication for periodontal surgery.
* Patients who are able to maintain good oral hygiene.
* Gingival thickness for the site selected should be ≥1mm.
* Probing depth of ≥ 6mm.
* Patient has at least one hopeless teeth

Exclusion Criteria

* Active infectious diseases (hepatitis, tubercu¬losis, HIV, etc….).
* Medically compromised patients.
* Smokers and alcoholic abusers
* People who suffer from any systemic disease that affect the periodontium.
* Pregnant, postmenopausal women.
* People who take anti-inflammatory drugs, anti¬biotics or vitamins within the previous 3 month.
* People who use mouth washes regularly
* Participants in other clinical trials.
Minimum Eligible Age

16 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

October 6 University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Enas Elgendy

Professor of Periodontology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

October 6 University

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Elgendy EA, Elgendy AM, ElBorady OM. Clinical And Radiographic Assessment Of Autogenous Dentin Nanoparticles In Treatment Of Stage Iii Periodontitis: A Split-Mouth Clinical Study. J Pak Med Assoc. 2023 Apr;73(Suppl 4)(4):S310-S316. doi: 10.47391/JPMA.EGY-S4-60.

Reference Type DERIVED
PMID: 37482878 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.